Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: A North Central Cancer Treatment Group Phase III Double-Blind Placebo-Controlled Trial

James A. Martenson, John W. Bollinger, Jeff A Sloan, Paul J. Novotny, Rodolfo E. Urias, John C. Michalak, Thomas G. Shanahan, James A. Mailliard, Ralph Levitt

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Purpose: Randomized studies have suggested that sucralfate is effective in mitigating diarrhea during pelvic radiation therapy (RT). This North Central Cancer Treatment Group study was undertaken to confirm the antidiarrheal effect of sucralfate. Several other measures of bowel function were also assessed. Patients and Methods: Patients receiving pelvic RT to a minimum of 45 Gy at 1.7 to 2.1 Gy/d were eligible for the study. Patients were assigned randomly, in double-blind fashion, to receive sucralfate (1.5 g orally every 6 hours) or an identical looking placebo during pelvic RT. Results: One hundred twenty-three patients were randomly assigned and found assessable. Overall, there was no significant difference in patient characteristics between those receiving sucralfate and those receiving placebo. Moderate or worse diarrhea was observed in 53% of patients receiving sucralfate versus 41% of those receiving placebo. Compared with patients receiving placebo, more sucralfate-treated patients reported fecal incontinence (16% v 34%, respectively; P = .04) and need for protective clothing (8% v 23%, respectively; P = .04). The incidence and severity of nausea were worse among those taking sucralfate (P = .03). Analysis of patient-reported symptoms 10 to 12 months after RT showed a nonsignificant trend toward more problems in patients taking sucralfate than in those taking placebo (average, 2.3 v 1.9 problems, respectively; P = .34). Conclusion: Sucralfate did not decrease pelvic RT-related bowel toxicity by any of the end points measured and seems to have aggravated some gastrointestinal symptoms. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish (US)
Pages (from-to)1239-1245
Number of pages7
JournalJournal of Clinical Oncology
Volume18
Issue number6
StatePublished - Mar 2000

Fingerprint

Sucralfate
Diarrhea
Radiotherapy
Placebos
Neoplasms
Therapeutics
Protective Clothing
Antidiarrheals
Fecal Incontinence
Nausea

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy : A North Central Cancer Treatment Group Phase III Double-Blind Placebo-Controlled Trial. / Martenson, James A.; Bollinger, John W.; Sloan, Jeff A; Novotny, Paul J.; Urias, Rodolfo E.; Michalak, John C.; Shanahan, Thomas G.; Mailliard, James A.; Levitt, Ralph.

In: Journal of Clinical Oncology, Vol. 18, No. 6, 03.2000, p. 1239-1245.

Research output: Contribution to journalArticle

Martenson, James A. ; Bollinger, John W. ; Sloan, Jeff A ; Novotny, Paul J. ; Urias, Rodolfo E. ; Michalak, John C. ; Shanahan, Thomas G. ; Mailliard, James A. ; Levitt, Ralph. / Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy : A North Central Cancer Treatment Group Phase III Double-Blind Placebo-Controlled Trial. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 6. pp. 1239-1245.
@article{77e95704d2ac4159a83f8c3ba023010c,
title = "Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: A North Central Cancer Treatment Group Phase III Double-Blind Placebo-Controlled Trial",
abstract = "Purpose: Randomized studies have suggested that sucralfate is effective in mitigating diarrhea during pelvic radiation therapy (RT). This North Central Cancer Treatment Group study was undertaken to confirm the antidiarrheal effect of sucralfate. Several other measures of bowel function were also assessed. Patients and Methods: Patients receiving pelvic RT to a minimum of 45 Gy at 1.7 to 2.1 Gy/d were eligible for the study. Patients were assigned randomly, in double-blind fashion, to receive sucralfate (1.5 g orally every 6 hours) or an identical looking placebo during pelvic RT. Results: One hundred twenty-three patients were randomly assigned and found assessable. Overall, there was no significant difference in patient characteristics between those receiving sucralfate and those receiving placebo. Moderate or worse diarrhea was observed in 53{\%} of patients receiving sucralfate versus 41{\%} of those receiving placebo. Compared with patients receiving placebo, more sucralfate-treated patients reported fecal incontinence (16{\%} v 34{\%}, respectively; P = .04) and need for protective clothing (8{\%} v 23{\%}, respectively; P = .04). The incidence and severity of nausea were worse among those taking sucralfate (P = .03). Analysis of patient-reported symptoms 10 to 12 months after RT showed a nonsignificant trend toward more problems in patients taking sucralfate than in those taking placebo (average, 2.3 v 1.9 problems, respectively; P = .34). Conclusion: Sucralfate did not decrease pelvic RT-related bowel toxicity by any of the end points measured and seems to have aggravated some gastrointestinal symptoms. (C) 2000 by American Society of Clinical Oncology.",
author = "Martenson, {James A.} and Bollinger, {John W.} and Sloan, {Jeff A} and Novotny, {Paul J.} and Urias, {Rodolfo E.} and Michalak, {John C.} and Shanahan, {Thomas G.} and Mailliard, {James A.} and Ralph Levitt",
year = "2000",
month = "3",
language = "English (US)",
volume = "18",
pages = "1239--1245",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy

T2 - A North Central Cancer Treatment Group Phase III Double-Blind Placebo-Controlled Trial

AU - Martenson, James A.

AU - Bollinger, John W.

AU - Sloan, Jeff A

AU - Novotny, Paul J.

AU - Urias, Rodolfo E.

AU - Michalak, John C.

AU - Shanahan, Thomas G.

AU - Mailliard, James A.

AU - Levitt, Ralph

PY - 2000/3

Y1 - 2000/3

N2 - Purpose: Randomized studies have suggested that sucralfate is effective in mitigating diarrhea during pelvic radiation therapy (RT). This North Central Cancer Treatment Group study was undertaken to confirm the antidiarrheal effect of sucralfate. Several other measures of bowel function were also assessed. Patients and Methods: Patients receiving pelvic RT to a minimum of 45 Gy at 1.7 to 2.1 Gy/d were eligible for the study. Patients were assigned randomly, in double-blind fashion, to receive sucralfate (1.5 g orally every 6 hours) or an identical looking placebo during pelvic RT. Results: One hundred twenty-three patients were randomly assigned and found assessable. Overall, there was no significant difference in patient characteristics between those receiving sucralfate and those receiving placebo. Moderate or worse diarrhea was observed in 53% of patients receiving sucralfate versus 41% of those receiving placebo. Compared with patients receiving placebo, more sucralfate-treated patients reported fecal incontinence (16% v 34%, respectively; P = .04) and need for protective clothing (8% v 23%, respectively; P = .04). The incidence and severity of nausea were worse among those taking sucralfate (P = .03). Analysis of patient-reported symptoms 10 to 12 months after RT showed a nonsignificant trend toward more problems in patients taking sucralfate than in those taking placebo (average, 2.3 v 1.9 problems, respectively; P = .34). Conclusion: Sucralfate did not decrease pelvic RT-related bowel toxicity by any of the end points measured and seems to have aggravated some gastrointestinal symptoms. (C) 2000 by American Society of Clinical Oncology.

AB - Purpose: Randomized studies have suggested that sucralfate is effective in mitigating diarrhea during pelvic radiation therapy (RT). This North Central Cancer Treatment Group study was undertaken to confirm the antidiarrheal effect of sucralfate. Several other measures of bowel function were also assessed. Patients and Methods: Patients receiving pelvic RT to a minimum of 45 Gy at 1.7 to 2.1 Gy/d were eligible for the study. Patients were assigned randomly, in double-blind fashion, to receive sucralfate (1.5 g orally every 6 hours) or an identical looking placebo during pelvic RT. Results: One hundred twenty-three patients were randomly assigned and found assessable. Overall, there was no significant difference in patient characteristics between those receiving sucralfate and those receiving placebo. Moderate or worse diarrhea was observed in 53% of patients receiving sucralfate versus 41% of those receiving placebo. Compared with patients receiving placebo, more sucralfate-treated patients reported fecal incontinence (16% v 34%, respectively; P = .04) and need for protective clothing (8% v 23%, respectively; P = .04). The incidence and severity of nausea were worse among those taking sucralfate (P = .03). Analysis of patient-reported symptoms 10 to 12 months after RT showed a nonsignificant trend toward more problems in patients taking sucralfate than in those taking placebo (average, 2.3 v 1.9 problems, respectively; P = .34). Conclusion: Sucralfate did not decrease pelvic RT-related bowel toxicity by any of the end points measured and seems to have aggravated some gastrointestinal symptoms. (C) 2000 by American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=0034021855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034021855&partnerID=8YFLogxK

M3 - Article

C2 - 10715293

AN - SCOPUS:0034021855

VL - 18

SP - 1239

EP - 1245

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -